Pharmacotherapy in Temporomandibular Disorders: A Review

Area of Science:

• Pharmacology
• Oral and Maxillofacial Surgery
• Pain Management

Background:

• Temporomandibular disorder (TMD) encompasses joint and muscle issues, affecting 33% of the population.
• TMD symptoms include pain, restricted jaw movement, and can be exacerbated by psychological factors.
• Prevalence is highest in adults aged 20-40, with many cases resolving over time, but some persisting for over a year.

Purpose of the Study:

• To review the pharmacology of commonly prescribed agents for TMD.
• To discuss potential adverse drug reactions and interactions associated with TMD pharmacotherapy.
• To provide insights into the risks and benefits of various drug classes used in TMD management.

Main Methods:

• Literature review of pharmacological agents used for TMD treatment.
• Analysis of drug classes including NSAIDs, opioids, corticosteroids, muscle relaxants, antidepressants, anticonvulsants, and benzodiazepines.
• Examination of existing research and evidence, including a Cochrane study on pharmacotherapy for TMD.

Main Results:

• Commonly used TMD medications include NSAIDs, opioids, corticosteroids, muscle relaxants, antidepressants, anticonvulsants, and benzodiazepines.
• The review details the pharmacology of these agents and their associated risks.
• Understanding drug risks and benefits is crucial for selecting appropriate TMD pharmacotherapy.

Conclusions:

• Pharmacological interventions are a key component in managing TMD pain and symptoms.
• A comprehensive understanding of drug profiles, including adverse effects and interactions, is essential for effective patient care.
• Informed selection of pharmacologic agents can optimize treatment outcomes for individuals with temporomandibular disorders.